Synonyms: CBR-2092 | TNP-2092
Compound class:
Synthetic organic
Comment: Rifaquizinone (formerly CBR-2092, then TNP-2092) is a rifamycin-quinolone hybrid antibacterial compound [2]. It exerts combined effects on bacterial RNA polymerase, DNA gyrase and DNA topoisomerase IV, although RNA polymerase has been reporetd as the primary cellular target [4]. Rifaquizinone was developed for potential to treat biofilm associated infections such as those caused by staphylococci [3-4]. Initial development was by Cumbre Pharmaceuticals, but it is now being taken forward by TenNor Therapeutics, hence the change in research code.
|
|
Classification | |
Compound class | Synthetic organic |
International Nonproprietary Names | |
INN number | INN |
12336 | rifaquizinone |
Synonyms |
CBR-2092 | TNP-2092 |
Database Links | |
Specialist databases | |
Antibiotic DB | CBR-2092, TNP-2092, Rifaquizinone |
Other databases | |
CAS Registry No. | 922717-97-3 (source: Scifinder) |
GtoPdb PubChem SID | 405560469 |
PubChem CID | 137253362 |
Search Google for chemical match using the InChIKey | OPZFMLLAJBIKAN-KYGXCNJYSA-N |
Search Google for chemicals with the same backbone | OPZFMLLAJBIKAN |
Search PubMed clinical trials | rifaquizinone |
Search PubMed titles | rifaquizinone |
Search PubMed titles/abstracts | rifaquizinone |
UniChem Compound Search for chemical match using the InChIKey | OPZFMLLAJBIKAN-KYGXCNJYSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | OPZFMLLAJBIKAN-KYGXCNJYSA-N |